findmyKOL
Clinical trialNCT03528642Active, not recruitingPhase 1Interventional

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

SponsorNational Cancer Institute (NCI)Enrollment40Astrocytoma, IDH-Mutant, Grade 2Astrocytoma, IDH-Mutant, Grade 3
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona, United States

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, United States

  • Uc San Diego Moores Cancer Center

    La Jolla, California, United States

  • Uc Irvine Health/chao Family Comprehensive Cancer Center

    Orange, California, United States

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia, United States

  • Mayo Clinic in Florida

    Jacksonville, Florida, United States

  • Moffitt Cancer Center

    Tampa, Florida, United States

  • University of Iowa/holden Comprehensive Cancer Center

    Iowa City, Iowa, United States

  • University of Kentucky/markey Cancer Center

    Lexington, Kentucky, United States

  • Johns Hopkins University/sidney Kimmel Cancer Center

    Baltimore, Maryland, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, United States

  • Siteman Cancer Center at Saint Peters Hospital

    City of Saint Peters, Missouri, United States

  • Siteman Cancer Center at West County Hospital

    Creve Coeur, Missouri, United States

  • Siteman Cancer Center at Christian Hospital

    St Louis, Missouri, United States

  • Siteman Cancer Center-South County

    St Louis, Missouri, United States

  • Washington University School of Medicine

    St Louis, Missouri, United States

  • Laura and Isaac Perlmutter Cancer Center at Nyu Langone

    New York, New York, United States

  • Nyp/columbia University Medical Center/herbert Irving Comprehensive Cancer Center

    New York, New York, United States

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, United States

  • University of Pittsburgh Cancer Institute (upci)

    Pittsburgh, Pennsylvania, United States

  • Ut Md Anderson Cancer Center

    Houston, Texas, United States

  • Huntsman Cancer Institute/university of Utah

    Salt Lake City, Utah, United States

  • University of Virginia Cancer Center

    Charlottesville, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 May 2019
Primary completion
11 Sept 2026
Completion
11 Sept 2026
Last update posted
17 Jun 2026
Registered enrollment
40
Registry id
NCT03528642

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.